{"id":2371,"date":"2018-06-05T11:25:29","date_gmt":"2018-06-05T11:25:29","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=2371"},"modified":"2018-06-05T11:25:29","modified_gmt":"2018-06-05T11:25:29","slug":"biocentury-enyo-aims-for-phase-ii-hbv-nash-trails-with-e40m-round","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/biocentury-enyo-aims-for-phase-ii-hbv-nash-trails-with-e40m-round\/","title":{"rendered":"BioCentury &#8211; ENYO aims for Phase II, HBV, NASH trails with \u20ac40m round"},"content":{"rendered":"<p><\/center><a href=\"https:\/\/www.biocentury.com\/bc-extra\/financial-news\/2018-06-04\/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round\" target=\"_blank\" rel=\"noopener\">https:\/\/www.biocentury.com\/bc-extra\/financial-news\/2018-06-04\/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"https:\/\/www.biocentury.com\/bc-extra\/financial-news\/2018-06-04\/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round\" target=\"_blank\" rel=\"noopener\">https:\/\/www.biocentury.com\/bc-extra\/financial-news\/2018-06-04\/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-2371","post","type-post","status-publish","format-standard","hentry","category-media-coverage-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/media-coverage-fr\/\" rel=\"category tag\">Couverture m\u00e9diatique<\/a>","rttpg_excerpt":"https:\/\/www.biocentury.com\/bc-extra\/financial-news\/2018-06-04\/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2371"}],"version-history":[{"count":1,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2371\/revisions"}],"predecessor-version":[{"id":2372,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2371\/revisions\/2372"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=2371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=2371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}